Identification of potential therapeutic antimicrobial peptides against Acinetobacter baumannii in a mouse model of
Chiau-Jing Jung1, You-Di Liao2, Chih-Chieh Hsu3
1Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, No. 250, Wuxing Street, Taipei, 11031, Taiwan. cjjung@tmu.edu.tw.
Abstract:
Acinetobacter baumannii-induced nosocomial pneumonia has become a serious clinical problem because of high antibiotic resistance rates. Antimicrobial peptides (AMP) are an ideal alternative strategy due to their broad-spectrum of antimicrobial activity and low incidence of bacterial resistance. However, their application is limited by toxicity and stability in vivo. The present study used a mouse model to directly identify potential AMPs effective for treatment of A. baumannii-induced pneumonia. Fifty-eight AMPs were screened and two identified (SMAP-29 and TP4) to have prophylactic effects which prevented the death of mice with pneumonia. Furthermore, two TP4 derivatives (dN4 and dC4) were found to have therapeutic activity in pneumonia mouse models by peritoneal or intravenous administration. Both dN4 and dC4 also inhibited and/or eliminated A. baumannii biofilms at higher doses. Taken together, these data suggest the AMP derivatives dN4 and dC4 represent a potential treatment strategy for A. baumannii-induced pneumonia.
Insights
New antimicrobial peptides (AMPs) show promise for treating Acinetobacter baumannii pneumonia. Derivatives dN4 and dC4 effectively treated pneumonia in mice and inhibited bacterial biofilms.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Acinetobacter baumannii causes difficult-to-treat nosocomial pneumonia due to high antibiotic resistance.
- Antimicrobial peptides (AMPs) offer a potential alternative due to broad-spectrum activity and low resistance development.
- Existing AMPs face challenges with in vivo toxicity and stability.
Purpose of the Study:
- To identify effective antimicrobial peptides (AMPs) for treating Acinetobacter baumannii-induced pneumonia using a mouse model.
- To evaluate the prophylactic and therapeutic potential of identified AMPs and their derivatives.
Main Methods:
- Screening of 58 antimicrobial peptides (AMPs) in a mouse model of Acinetobacter baumannii pneumonia.
- Administration of identified AMPs (SMAP-29, TP4) and TP4 derivatives (dN4, dC4) via peritoneal or intravenous routes.
- Assessment of prophylactic effects on survival and therapeutic effects on pneumonia, including inhibition of bacterial biofilms.
Main Results:
- Two AMPs, SMAP-29 and TP4, demonstrated prophylactic effects, preventing mortality in pneumonia-induced mice.
- TP4 derivatives, dN4 and dC4, exhibited therapeutic efficacy in treating pneumonia when administered systemically.
- dN4 and dC4 also showed inhibitory and/or eradicating effects on Acinetobacter baumannii biofilms at higher concentrations.
Conclusions:
- The identified AMP derivatives, dN4 and dC4, represent promising candidates for novel therapeutic strategies against Acinetobacter baumannii pneumonia.
- These AMP derivatives may offer a viable alternative to conventional antibiotics, addressing challenges of resistance and biofilm formation.
More Related Videos
04:32Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
07:43A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice
Published on: September 28, 2016